A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Digoxin in Healthy Male and Female Adults.
Latest Information Update: 12 May 2021
At a glance
- Drugs Sucroferric oxyhydroxide (Primary) ; Digoxin
- Indications Heart failure; Hyperphosphataemia; Ischaemic heart disorders
- Focus Pharmacokinetics
- Sponsors Vifor
- 17 Jan 2012 Actul end date Jan 2012 added as reported by ClinicalTrials.gov.
- 17 Jan 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 24 Nov 2011 New trial record